Program Snapshot

The Regenerative Medicine Program efforts aimed to accelerate breakthroughs in the development of stem cell-based therapies for complex diseases. The overall goal of the program was to develop resources to catalyze therapeutic use of a special type of stem cells called induced pluripotent stem cells (iPSCs). RMP consisted of two initiatives: (1) the Stem Cell Translation Laboratory (SCTL), headed by Dr. Ilyas Singec, within the National Center for Advancing Translational Sciences (NCATS); and (2) a Therapeutic Challenge Award to Dr. Kapil Bharti at the National Eye Institute (NEI). RMP also supported distribution of induced pluripotent stem cell lines developed by the program for laboratory and clinical research.

RMP has transitioned from Common Fund support. Common Fund programs are strategic investments that achieve a set of high-impact goals within a 5-10 year timeframe. At the conclusion of each program, deliverables will transition to other sources of support or use within the scientific community.

 RMP was supported by the Common Fund from 2010 to 2020.Currently, the Stem Cell Translation Laboratory (SCTL) is being supported by the National Center for Advancing Translational Sciences (NCATS). Dr. Kapil Bharti and his team at the NIH National Eye Institute are conducting the first clinical trial to test the safety of a new stem cell therapy for vision loss among dry age-related macular degeneration (AMD) patients. RMP-generated induced pluripotent stem cell lines are being managed by NINDS and distributed through RUCDR Infinite Biologics at Rutgers University. 

Highlights of the Regenerative Medicine program’s major accomplishments are:


  • Developed a  clinical-grade, current Good Manufacturing Practice (cGMP) iPSC line and 14 research-grade iPSC lines
  • Dr. Bharti and his team conducted pre-clinical research to develop a novel iPSC-based therapy to prevent blindness in animal models of retinal degeneration. Findings from this study  informed the first-in-human clinical trial to treat AMD that may lead to new treatments that will prevent blindness in older individuals.
  •  The SCTL established a new resource that can help bring induced pluripotent stem cell technology closer to clinical applications

Please note that since the Regenerative Medicine Program is no longer supported by the Common Fund, the program website is being maintained as an archive and will not be updated on a regular basis. 


This page last reviewed on April 11, 2023